James N Chang

6635654, Oct 21, 2003

Jan 9, 2003

10/340355

Chin-Ming Chang - Tustin TX
Eldon Q. Farnes - Laguna Beach CA
Orest Olejnik - Coto De Caza CA
James N. Chang - Newport Beach CA

Allergan, Inc. - Irvine CA

A61K 3144

514290

The present invention is directed to an ophthalmic formulation which comprises a therapeutically effective amount of ethyl 4-(8-chloro-5,6-dihydro-11-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)-1-piperidinecarboxylate, known as loratadine, a fatty acid ester, and a surfactant, which has been found to be useful in treating ocular allergies, especially allergic conjunctivitis, and related conditions.

6650438, Nov 18, 2003

Dec 1, 1999

09/452815

William C. Kress - Mission Viejo CA
James Z. Chang - Vancouver WA

Sharp Laboratories of America, Inc, - Camas WA

G06K 1500

358 19, 358 21

A method of transforming scanned RGB values into a colorimetric color space includes identifying multiple input media types to be scanned; assigning a weighting factor to each input media type; dividing input color space into segments; assigning a weighting factor to each input color space segment; applying regression and interpolation techniques to minimize color error; and generating a colorimetric output.

6933289, Aug 23, 2005

Jul 1, 2003

10/613097

Robert T. Lyons - Laguna Hills CA, US
James N. Chang - Newport Beach CA, US

Allergan, Inc. - Irvine CA

A61K031/715
A61K009/14
C07C059/00
C07C059/147
C07C059/185

514 58, 554214, 554117, 514530, 5147724, 424488

This invention relates to a method of reducing an irritating or adverse side effect associated with the topical use of an active ophthalmic drug comprising incorporating an effective amount of a cyclodextrin or cyclodextrin derivative into a formulation to complex the active drug such that the concentration of the free active drug is reduced below a tolerable threshold, and incorporating an effective amount of a viscosity increasing agent in said formulation such that the bioavailability of said drug is high enough to be therapeutically effective, wherein the cyclodextrin or cyclodextrin derivative is not required to solubilize the active drug. Another aspect of this invention relates to topical ophthalmic formulations comprising an active drug, a cyclodextrin or cyclodextrin derivative, and a viscosity-enhancing agent, in effective amounts as stated above.

6959015, Oct 25, 2005

May 9, 2001

09/852819

Jin H. Hwang - Cerritos CA, US
James C. Chang - Cypress CA, US
Mark L. Yang - Irvine CA, US

Crest Microsystems - Cerritos CA

H04J003/06
H04L025/00
G06F001/12

370516, 370503, 370506, 375372, 713400

The invention provides a novel scheme to align data streams across multiple transmission channels and match multiple transmissions with one receiving rate. The channel aligning aspect of this invention detects the occurrence of an aligning character in a plurality of input channel character streams, buffers the character stream until an aligning character has been detected on every input channel. The channel aligning system transmits filler characters over every output channel corresponding to an input channel where an aligning character has been received if an aligning character has not been detected on every input channel. The aligning system then synchronously transmits the buffered characters, starting with the aligning character and proceeding with the subsequently received characters. The rate matching aspect of this invention receives a plurality of character streams synchronized by a first clock and buffers the character streams. Buffered characters are then transmitted over one or more output channels synchronized by a second clock.

6969706, Nov 29, 2005

May 12, 2004

10/844647

Chin-Ming Chang - Tustin CA, US
James Chang - Newport Beach CA, US
Robert T. Lyons - Laguna Hills CA, US

Allergan, Inc. - Irvine CA

A61K031/724

514 60, 514912, 514914, 514970, 536103

A composition comprising a cyclodextrin, a guanidine-based cationic compound, and sorbic acid is disclosed herein. Preservatives and methods related thereto, and experimental results suggesting certain advantages related to these compositions, preservatives, and methods are also presented herein.

7045121, May 16, 2006

Dec 14, 2001

10/017817

James N. Chang - Newport Beach CA, US
Teresa H. Kuan - Placentia CA, US

Allergan, Inc. - Irvine CA

A61K 31/47

424 7804, 514 57, 514912

Ophthalmic compositions include an ophthalmically acceptable carrier component, for example, an aqueous-based carrier, and a plurality of polyanionic component portions having different molecular weights. In one embodiment, the polyanionic component includes a first polyanionic component portion having a first molecular weight; and a second polyanionic component portion having a different second molecular weight. Each of the first and second polyanionic component portions is present in an amount effective to provide lubrication to an eye when the composition is administered to an eye. Methods of making and using such compositions are also disclosed.

7202209, Apr 10, 2007

Jul 13, 2005

11/181428

James N. Chang - Newport Beach CA, US
Orest Olejnik - Coto De Caza CA, US
Bruce A. Firestone - Irvine CA, US

Allergan, Inc. - Irvine CA

A61K 38/12

514 9, 530317, 514912, 514975, 435112

A composition comprising a therapeutically effective amount of cyclosporin A, a blend of oils having a specific gravity of from 0. 90 to 1. 07, and a surfactant is disclosed herein.

7276476, Oct 2, 2007

Jul 13, 2005

11/181187

James N. Chang - Newport Beach CA, US
Orest Olejnik - Coto De Caza CA, US
Bruce A. Firestone - Irvine CA, US

Allergan, Inc. - Irvine CA

A61K 38/12

514 9, 530317, 514912, 514975, 435112

A composition comprising from 0. 001% to about 0. 4% cyclosporin A, a surfactant, and an oil selected from the group consisting of anise oil, clove oil, cassia oil, cinnamon oil, and combinations thereof, wherein said composition is an ophthalmically acceptable emulsion is disclosed herein.